Lung imaging - Two dimensional gamma scintigraphy, SPECT, CT and PET

Advanced Drug Delivery Reviews

Volumn 64, Issue 4, 2012, Pages 357-368

  Conway, Joy ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

CT; Drug deposition; Gamma scintigraphy; HRCT; Lung anatomy; Lung imaging; PET; SPECT

Indexed keywords

CT; GAMMA SCINTIGRAPHY; HRCT; LUNG ANATOMY; LUNG IMAGING; SPECT;

DRUG DELIVERY; IMAGING TECHNIQUES; NUCLEAR MEDICINE; POLYETHYLENE TEREPHTHALATES; TWO DIMENSIONAL;

BIOLOGICAL ORGANS;

CORTICOSTEROID; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUORODEOXYGLUCOSE F 18; INDIUM 111; IODINE 123; MANNITOL; NITROGEN 13; RESPIRATORY TRACT AGENT; TECHNETIUM 99M;

AEROSOL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; ECHO PLANAR IMAGING; ENDOBRONCHIAL ULTRASONOGRAPHY; FUNCTIONAL ANATOMY; GAMMA SCINTIGRAPHY; HUMAN; INHALER; ISOTOPE LABELING; LUNG ALVEOLUS EPITHELIUM; LUNG SCINTISCANNING; LUNG VENTILATION PERFUSION RATIO; METERED DOSE INHALER; MUCOCILIARY CLEARANCE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL RESOLUTION; PARTICLE SIZE; POSITRON EMISSION TOMOGRAPHY; POWDER INHALER; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOFT MIST INHALER; THREE DIMENSIONAL IMAGING; TWO DIMENSIONAL GAMMA SCINTIGRAPHY;

ADMINISTRATION, INHALATION; AEROSOLS; HUMANS; LUNG; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; SPECTROMETRY, GAMMA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84858614873     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.01.013     Document Type: Review

References (110)

1. Abdelrahim M.E., Assi K.H., Chrystyn H. Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion. Br. J. Clin. Pharmacol. 2011, 71:608-610.
2. Bondesson E., Bengtsson T., Nilsson L.-erik, Wollmer P. Site of deposition and absorption of an inhaled hydrophilic solute. Br. J. Clin. Pharmacol. 2007, 63(6):722-731.
3. Newman S., Steed K., Hooper G., Källén A., Borgström L. Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. Pharm. Res. 1995, 12(2):231-236.
4. Singh D., Collarini S., Poli G., Acerbi D., Amadasi A., Rusca A. Effect of AeroChamber Plus(TM) on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. Br. J. Clin. Pharmacol. 2011, 72(6):932-939.
5. Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br. J. Clin. Pharmacol. 2001, 51:289-299.
6. Borgström L., Newman S., Weisz A., Morén F. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J. Pharm. Sci. 1992, 81(8):753-755.
7. O'Connor D., Adams W.P., Chen M.L., Daley-Yates P., Davis J., Derendorf H., Ducharme M.P., Fuglsang A., Herrle M., Hochhaus G., Holmes S.M., Lee S.L., Li B.V., Lyapustina S., Newman S., Oliver M., Patterson B., Peart J., Poochikian G., Roy P., Shah T., Singh G.J., Sharp S.S. Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24(3):119-135.
8. Howarth P. Why particle size should affect clinical response to inhaled therapy. J. Aerosol Med. 2001, 14(Suppl 1):S27-S34.
9. Carvalho T.C., Peters J.I., Williams R.O. Influence of particle size on regional lung deposition - what evidence is there?. Int. J. Pharm. 2011, 406:1-10.
10. Bennett W.D., Brown J.S., Zeman K.L., Hu S.C., Scheuch G., Sommerer K. Targeting delivery of aerosols to different lung regions. J. Aerosol Med. 2002, 15(2):179-188.
11. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am. J. Respir. Crit. Care Med. 2005, 172(12):1497-1504.
12. Piva J.P., Menna Barreto S.S., Zelmanovitz F., Amantéa S., Cox P. Heliox versus oxygen for nebulized aerosol therapy in children with lower airway obstruction. Pediatr. Crit. Care Med. 2002, 3(1):6-10.
13. I.K. Katz, G. Caillibotte, M. Pichelin, C. Majoral, A.R. Martin, J. Texereau, J. Conway, J. Fleming, L. Tossici-Bolt, Aerosol deposition patterns breathing helium-oxygen vs. air as determined by 3D SPECT, J Aerosol Med Pulm Drug Deliv. 24 (3) (2011) A-34. (Proceedings of the 18th Congress of the International Society for Aerosols in Medicine 2011, Rotterdam, the Netherlands).
14. Usmani O.S., Barnes P.J. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann. Med. 2011, 1-11.
15. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6:67-74.
16. Gumbleton M., Taylor G. Challenges and innovations in effective pulmonary systemic and macromolecular drug delivery. Adv. Drug Deliv. Rev. 2006, 58:993-995.
17. Scheuch G., Kohlhaeufl M.J., Brand P., Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv. Drug Deliv. Rev. 2006, 58:996-1008.
18. Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003, 56:588-599.
19. Dolovich M.B., Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011, 377:1032-1045.
20. Newman S., Fleming J. Challenges in assessing regional distribution of inhaled drug in the human lungs. Expert Opin. Drug Deliv. 2011, 8(7):841-855.
21. Fleming J., Conway J., Majoral C., Tossici-Bolt L., Caillibotte G., Perchet D., Pichelin M., Muellinger B., Martonen T., Kronenburg P., Apiou-Sbirlea G. The use of combined single photon emission computed tomography and X-ray computed tomography to assess the fate of inhaled aerosol. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24(1):49-60.
22. Scheuch G., Bennett W., Borgström L., Clark A., Dalby R., Dolovich M., Fleming J., Gehr P., Gonda I., O'Callaghan C., Taylor G., Newman S. Deposition, imaging, and clearance: what remains to be done?. J. Aerosol Med. Pulm. Drug Deliv. Suppl. 2010, 2:S39-S57.
23. Coates A.L., Green M., Leung K., Chan J., Ribeiro N., Louca E., et al. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. Pediatr. Pulmonol. 2008, 43:753-759.
24. Häussermann S., Acerbi D., Brand P., Herpich C., Poli G., Sommerer K., Meyer T. Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients. J. Aerosol Med. 2007, 20(3):331-341.
25. Condos R. Regional deposition of aerosolized interferon-γ in pulmonary tuberculosis. Chest 2004, 125:2146-2155.
26. Weers J., Metzheiser B., Taylor G., Warren S., Meers P., Perkins W.R. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J. Aerosol Med. Pulm. Drug Deliv. 2009, 22(2):131-138.
27. Glover W., Chan H.-K., Eberl S., Daviskas E., Verschuer J. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int. J. Pharm. 2008, 349:314-322.
28. Dolovich M.B. 18F-fluorodeoxyglucose positron emission tomographic imaging of pulmonary functions, pathology, and drug delivery. Proc. Am. Thoracic Soc. 2009, 6:477-485.
29. Farr S.J. The physico-chemical basis of radiolabelling metered dose inhalers with 99mTc. J Aerosol Med. Suppl 1996, 1:S27-S36.
30. Farr S.J., Warren S.J., Lloyd P., Okikawa J.K., Schuster J.A., Rowe A.M. Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. Int. J. Pharm. 2000, 198:63-70.
31. Ball D.J., Hirst P.H., Newman S.P., Sonet B., Streel B., Vanderbist F. Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device. Int. J. Pharm. 2002, 245:123-132.
32. Walker P.S., Petterson G.L., Bondesson E., Conway J.H. An advanced and detailed in vitro validation procedure for the radiolabeling of carrier-free terbutaline sulphate dry powder. J. Aerosol Med. 2001, 14(2):227-236.
33. Walker P.S., Conway J.H., Fleming J.S., Bondesson E., Borgström L. Pulmonary clearance rate of two chemically different forms of inhaled pertechnetate. J. Aerosol Med. 2001, 14(2):209-215.
34. Bräuner E.V., Mortensen J., Møller P., Bernard A., Vinzents P., Wåhlin P., et al. Effects of ambient air particulate exposure on blood-gas barrier permeability and lung function. Inhal. Toxicol. 2009, 21:38-47.
35. Eberl S., Chan H.-K., Daviskas E., Constable C., Young I. Aerosol deposition and clearance measurement: a novel technique using dynamic SPET. Eur. J. Nucl. Med. Mol. Imaging 2001, 28:1365-1372.
36. Wu Y., Kotzer C.J., Makrogiannis S., Logan G.A., Haley H., Barnette M.S. A noninvasive [(99m)Tc]DTPA SPECT/CT imaging methodology as a measure of lung permeability in a guinea pig model of COPD. Molecular Imaging and Biology: MIB: The Official Publication Of the Academy of Molecular Imaging 2010.
37. Coates A.L., Green M., Leung K., Chan J., Ribeiro N., Ratjen F., Charron M. A comparison of amount and speed of deposition between the PARI LC STAR(®) jet nebulizer and an investigational eFlow(®) nebulizer. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24(3):157-163.
38. Marthin J.K., Mortensen J., Pressler T., Nielsen K.G. Pulmonary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia. Chest 2007, 132:966-976.
39. Bennett W.D., Herbst M., Alexis N.E., Zeman K.L., Wu J., Hernandez M.L. Effect of inhaled dust mite allergen on regional particle deposition and mucociliary clearance in allergic asthmatics. Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol. 2011, 1-10.
40. Lindström M., Camner P., Falk R., Hjelte L., Philipson K., Svartengren M. Long-term clearance from small airways in patients with cystic fibrosis. Eur. Respir. J. Off. J. Eur. Soc. Clin. Respir. Physiol. 2005, 25:317-323.
41. Lindström M., Falk R., Hjelte L., Philipson K., Svartengren M. Long-term clearance from small airways in subjects with ciliary dysfunction. Respir. Res. 2006, 7:79.
42. Virgolini I., Kurtaran A., Leimer M., Smith-Jones P., Agis H., Angelberger P. Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1997, 38:1475-1481.
43. 111Indium-labeled ultrafine carbon particles; a novel aerosol for pulmonary deposition and retention studies. Inhal. Toxicol. 2011, 23:121-128.
44. Warren S., Taylor G., Smith J., Buck H., Parry-Billings M. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique. J. Aerosol Med. 2002, 15(1):15-25.
45. Bondesson E., Bengtsson T., Borgström L., Nilsson L.E., Norrgren K., Trofast E., et al. Planar gamma scintigraphy-points to consider when quantifying pulmonary dry powder aerosol deposition. Int. J. Pharm. 2003, 258:227-240.
46. Brand P., Hederer B., Austen G., Dewberry H., Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int. J. Chronic Obstruct. Pulm. Dis. 2008, 3:763-770.
47. Clark A., Kuo M.-C., Newman S., Hirst P., Pitcairn G., Pickford M. A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. Pharm. Res. 2008, 25:1583-1590.
48. Behr J., Zimmermann G., Baumgartner R., Leuchte H., Neurohr C., Brand P., Herpich C., Sommerer K., Seitz J., Menges G., Tillmanns S., Keller M. Munich Lung Transplant Group, Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J Aerosol Med Pulm Drug Deliv. 2009, 22(2):121-130.
49. Cassidy J.P., Amin N., Marino M., Gotfried M., Meyer T., Sommerer K. Insulin lung deposition and clearance following Technosphere(®) insulin inhalation powder administration. Pharm. Res. 2011.
50. Lenney W., Edenborough F., Kho P., Kovarik J.M. Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J. Cystic Fibrosis Off. J. Eur. Cystic Fibrosis Soc. 2011, 10:9-14.
51. Biddiscombe M.F., Meah S.N., Underwood S.R., Usmani O.S. Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24(3):165-173.
52. Scheuch G., Bennett W., Borgström L., Clark A., Dalby R., Dolovich M., Fleming J., Gehr P., Gonda I., O'Callaghan C., Taylor G., Newman S. Deposition, imaging, and clearance: what remains to be done?. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23(Suppl 2):S39-S57.
53. K.L. Zeman, M. Xie, H. Hurd, SH Donaldson, J. Wu, W.D. Bennett, Comparison of 57co transmission scans and 133xenon equilibrium ventilation scans for analysis of regional particle deposition in lungs by gamma scintigraphy. J Aerosol Med Pul Deliv., 24 (3) (2011) A-40 (Proceedings of the 18th International Conference of the International Society for Aerosols in Medicine 2011, Rotterdam, the Netherlands).
54. Donaldson S.H., Corcoran T.E., Laube B.L., Bennett W.D. Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc. Am. Thoracic Soc. 2007, 4:399-405.
55. Sanders N.N., De Smedt S.C., Van Rompaey E., Simoens P., De Baets F., Demeester J. Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am. J. Respir. Crit. Care Med. 2000, 162:1905-1911.
56. Hida K., Lai S.K., Suk J.S., Won S.Y., Boyle M.P., Hanes J. Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. PLoS One 2011, 6:e19919.
57. Ibrahim B.M., Tsifansky M.D., Yang Y., Yeo Y. Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease. Expert Opinion On Drug Delivery 2011, 8:451-466.
58. Rogers D.F. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm. Pharmacol. Ther. 2005, 18:1-8.
59. Shur J., Nevell T.G., Ewen R.J., Price R., Smith A., Barbu E., et al. Cospray-dried unfractionated heparin with l-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy. J. Pharm. Sci. 2008, 97:4857-4868.
60. Edsbäcker S., Wollmer P., Selroos O., Borgström L., Olsson B., Ingelf J. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?. Pulm. Pharmacol. Ther. 2008, 21:247-258.
61. Meyer T., Reitmeir P., Brand P., Herpich C., Sommerer K., Schulze A., et al. Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD. Respir. Med. 2011, 105:900-906.
62. Daviskas E., Anderson S.D., Eberl S., Young I.H. Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction. Respir. Med. 2010, 104:1645-1653.
63. Corcoran T.E., Thomas K.M., Myerburg M.M., Muthukrishnan A., Weber L., Frizzell R. Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway. Eur. Respir. J. Off. J. Eur. Soc. Clin. Respir. Physiol. 2010, 35:781-786.
64. Pirildar T., Gumuser G., Ruksen E., Sakar A., Dinc G., Sayit E. Assessment of alveolar epithelial permeability with Tc-99m DTPA aerosol scintigraphy in patients with Sjogren syndrome. Rheumatol. Int. 2010, 30:599-604.
65. Lee J.W., Fang X., Krasnodembskaya A., Howard J.P., Matthay M.A. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells (Dayton, Ohio) 2011, 29:913-919.
66. Tillie-Leblond I., Gosset P., Le Berre R., Janin A., Prangère T., Tonnel A.B. Keratinocyte growth factor improves alterations of lung permeability and bronchial epithelium in allergic rats. Eur. Respir. J. Off. J. Eur. Soc. Clin. Respir. Physiol. 2007, 30:31-39.
67. Fleming J.S., Conway J.H., Bolt L., Holgate S.T. A comparison of planar scintigraphy and SPECT measurement of total lung deposition of inhaled aerosol. J. Aerosol Med. 2003, 16(1):9-19.
68. Newman S.P., Pitcairn G.R., Hirst P.H., Rankin L. Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv. Drug Deliv. Rev. 2003, 55:851-867.
69. Glover W., Chan H.-K., Eberl S., Daviskas E., Verschuer J. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int. J. Pharm. 2008, 349:314-322.
70. Klockare M., Dufva A., Danielsson A.-M., Hatherly R., Larsson S., Jacobsson H., et al. Comparison between direct humidification and nebulization of the respiratory tract at mechanical ventilation: distribution of saline solution studied by gamma camera. J Clin Nurs 2006, 15:301-307.
71. Eberl S., Chan H.K., Daviskas E. SPECT imaging for radioaerosol deposition and clearance studies. J. Aerosol Med. 2006, 19(1):8-20.
72. Eberl S., Chan H.-K., Daviskas E., Constable C., Young I. Aerosol deposition and clearance measurement: a novel technique using dynamic SPET. Eur. J. Nucl. Med. Mol. Imaging 2001, 28:1365-1372.
73. Fleming J.S., Nassim M., Hashish A.H., Bailey A.G., Conway J.H., Holgate S.T., et al. Three-dimensional description of pulmonary deposition of inhaled aerosol using data from multimodality imaging. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1996, 37:873-877.
74. Fleming J.S., Sauret V., Conway J.H., Martonen T.B. Validation of the conceptual anatomical model of the lung airway. J. Aerosol Med. 2004, 17(3):260-269.
75. Fleming J.S., Epps B.P., Conway J.H., Martonen T.B. Comparison of SPECT aerosol deposition data with a human respiratory tract model. J. Aerosol Med. 2006, 19(3):268-278.
76. Martonen T.B., Schroeter J.D., Fleming J.S. 3D in silico modeling of the human respiratory system for inhaled drug delivery and imaging analysis. Topology 2007, 96:603-617.
77. Fleming J.S. Measuring drug deposition by airway generation in humans. Respiratory Drug Delivery IX 2004, 187-193. Davis Healthcare International, River Grove. R.N. Dalby, P.R. Byron, J. Peart (Eds.).
78. Glover W., Chan H.-K., Eberl S., Daviskas E., Verschuer J. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int. J. Pharm. 2008, 349:314-322.
79. Chan H.K., Eberl S., Daviskas E., Constable C., Young I. Changes in lung deposition of aerosols due to hygroscopic growth: a fast SPECT study. J. Aerosol Med. 2002, 15(3):307-311.
80. King G.G., Harris B., Mahadev S. V/Q SPECT: utility for investigation of pulmonary physiology. Semin. Nucl. Med. 2010, 40:467-473.
81. Bajc M., Neilly J.B., Miniati M., Schuemichen C., Meignan M., Jonson B. EANM guidelines for ventilation/perfusion scintigraphy: part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:1356-1370.
82. Bajc M., Jonson B. Ventilation/perfusion SPECT for diagnosis of pulmonary embolism and other diseases. Int. J. Mol. Imaging 2011, 2011:682949.
83. Gutte H., Mortensen J., Jensen C.V., von der Recke P., Petersen C.L., Kristoffersen U.S., et al. Comparison of V/Q SPECT and planar V/Q lung scintigraphy in diagnosing acute pulmonary embolism. Nucl. Med. Commun. 2010, 31:82-86.
84. Stavngaard T., Søgaard L.V., Mortensen J., Hanson L.G., Schmiedeskamp J., Berthelsen A.K., et al. Hyperpolarized 3He MRI and 81mKr SPECT in chronic obstructive pulmonary disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:448-457.
85. Castro M., Fain S.B., Hoffman E.A., Gierada D.S., Erzurum S.C., Wenzel S. Lung imaging in asthmatic patients: the picture is clearer. J. Allergy Clin. Immunol. 2011, 1-12.
86. Hoffman E.A., Chon D. Computed tomography studies of lung ventilation and perfusion. Proc. Am. Thoracic Soc. 2005, 2:492-498. 506.
87. Tunon-de-Lara J.-M., Laurent F., Giraud V., Perez T., Aguilaniu B., Meziane H., et al. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J. Allergy Clin. Immunol. 2007, 119:583-590.
88. Busacker A., Newell J.D., Keefe T., Hoffman E.A., Granroth J.C., Castro M., Fain S., Wenzel S. A multivariate analysis of risk factors for the air trapping asthmatic population as measured by quantitative CT analysis. Chest 2010, 135(1):48-56.
89. Tschirren J., Hoffman E.A., McLennan G., Sonka M. Segmentation and quantitative analysis of intrathoracic airway trees from computed tomography images. Proc. Am. Thoracic Soc. 2005, 2:484-487. 503-4.
90. Lambert A.R., Shaughnessy P.O., Tawhai M.H., Hoffman E.A., Lin C.-L. Regional deposition of particles in an image-based airway model: large-eddy simulation and left-right lung ventilation asymmetry. Aerosol Sci. Technol. 2011, 45(1):11-25.
91. Sauret V., Halson P.M., Brown I.W., Fleming J.S., Bailey A.G. Study of the three-dimensional geometry of the central conducting airways in man using computed tomographic (CT) images. J. Anat. 2002, 200:123-134.
92. Inthavong K., Choi L.-T., Tu J., Ding S., Thien F. Micron particle deposition in a tracheobronchial airway model under different breathing conditions. Med. Eng. Phys. 2010, 32:1198-1212.
93. Montesantos S., Fleming J.S., Tossici-Bolt L. A spatial model of the human airway tree: the hybrid conceptual model. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23(1):59-68.
94. M. Bennett, T. Havelock, J. Conway, J. Fleming, Anatomically derived regional measurement of lung function or aerosol deposition, J Aerosol Med Pul Deliv., 24 (3) (2011) A-20 (Proceedings of the 18th International Conference of the International Society for Aerosols in Medicine 2011, Rotterdam, the Netherlands).
95. Lee Z., Berridge M.S. PET imaging-based evaluation of aerosol drugs and their delivery devices: nasal and pulmonary studies. IEEE Trans. Med. Imaging 2002, 21:1324-1331.
96. Berridge M.S., Lee Z., Heald D.L. Pulmonary distribution and kinetics of inhaled [11C]triamcinolone acetonide. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2000, 41:1603-1611.
97. Guenther K.J., Yoganathan S., Garofalo R., Kawabata T., Strack T., Labiris R., et al. Synthesis and in vitro evaluation of 18F- and 19F-labeled insulin: a new radiotracer for PET-based molecular imaging studies. J. Med. Chem. 2006, 49:1466-1474.
98. Iozzo P., Osman S., Glaser M., Knickmeier M., Ferrannini E., Pike V.W., et al. In vivo imaging of insulin receptors by PET: preclinical evaluation of iodine-125 and iodine-124 labelled human insulin. Nucl. Med. Biol. 2002, 29:73-82.
99. Dolovich M.B. 18F-fluorodeoxyglucose positron emission tomographic imaging of pulmonary functions, pathology, and drug delivery. Proc. Am. Thoracic Soc. 2009, 6:477-485.
100. Chen D.L., Ferkol T.W., Mintun M.A., Pittman J.E., Rosenbluth D.B., Schuster D.P. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. Am. J. Respir. Crit. Care Med. 2006, 173:1363-1369.
101. Jones H.A., Marino P.S., Shakur B.H., Morrell N.W. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur. Respir. J. 2003, 21:567-573.
102. Bellani G., Amigoni M., Pesenti A. Positron emission tomography in ARDS: a new look at an old syndrome. Minerva Anestesiol. 2011, 77(4):439-447.
103. Schroeder T., Melo M.F., Venegas J.G. Analysis of 2-[Fluorine-18]-Fluoro-2-deoxy-d-glucose uptake kinetics in PET studies of pulmonary inflammation. Acad. Radiol. 2011, 18(4):418-423.
104. Ojima F., Ido T., Hatazawa J., Itoh M., Shinohara H., Watanuki S., Seo S., Kai H., Takahama K., Ishii T., Nakagawa Y., Miyata T. Development of a new method for simultaneously evaluating mucociliary clearance and pulmonary epithelial permeability in rabbit experiments by means of 18FDG, three-dimensional positron emission tomography and rectilinear scan. Ann. Nucl. Med. 1998, 12(5):231-235.
105. Yanai M., Hatazawa J., Ojima F., Sasaki H., Itoh M., Ido T. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1998, 11:1342-1348.
106. Musch G., Venegas J.G. Positron emission tomography imaging of regional lung function. Minerva Anestesiol. 2006, 72(6):363-367.
107. Wellman T.J., Winkler T., Costa E.L.V., Musch G., Harris R.S., Venegas J.G. Measurement of regional specific lung volume change using respiratory-gated PET of inhaled 13N-nitrogen. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2010, 51:646-653.
108. Vidal Melo M.F., Winkler T., Harris R.S., Musch G., Greene R.E., Venegas J.G. Spatial heterogeneity of lung perfusion assessed with (13)N PET as a vascular biomarker in chronic obstructive pulmonary disease. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2010, 51:57-65.
109. Soja J., Grzanka P., Sladek K., Okon K., Cmiel A., Mikos M., et al. The use of endobronchial ultrasonography in assessment of bronchial wall remodeling in patients with asthma. Chest 2009, 136:797-804.
110. Coxson H.O., Mayo J., Lam S., Santyr G., Parraga G., Sin D.D. New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009, 180:588-597.